Sagimet Biosciences Q4 net loss narrows as R&D expenses fall

Reuters03-11

<a href="https://laohu8.com/S/SGMT">Sagimet Biosciences</a> Q4 net loss narrows as R&D expenses fall

Overview

U.S. biopharma firm's Q4 net loss narrowed yr/yr
Q4 research and development expense declined from prior year
Company completed Phase 1 trial for denifanstat/resmetirom combo and saw positive Phase 3 acne data from partner

Outlook

Sagimet plans Phase 2 denifanstat/resmetirom trial in F4 MASH patients in 2H 2026
Company expects to start Phase 2 TVB-3567 acne trial in 2026, pending Phase 1 completion

Result Drivers

R&D SPENDING - Q4 research and development expense declined by 52.6% yr/yr to $6.7 mln, contributing to a narrower net loss

Company press release: ID:nGNX7NkT6k

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 EPS		-$0.29
Q4 Net Income		-$9.57 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Sagimet Biosciences Inc is $27.00, about 388.2% above its March 10 closing price of $5.53

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618941265?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-11 19:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618941265","market":"fut","top_or_hot":-1,"title":"Sagimet Biosciences Q4 net loss narrows as R&D expenses fall","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/SGMT\">Sagimet Biosciences</a> Q4 net loss narrows as R&amp;D expenses fall</title></head><body><p><span>Overview</span></p><ul><li><p>U.S. biopharma firm's Q4 net loss narrowed yr/yr</p></li><li><p>Q4 research and development expense declined from prior year</p></li><li><p>Company completed Phase 1 trial for denifanstat/resmetirom combo and saw positive Phase 3 acne data from partner</p></li></ul><p><span>Outlook</span></p><ul><li><p>Sagimet plans Phase 2 denifanstat/resmetirom trial in F4 MASH patients in 2H 2026</p></li><li><p>Company expects to start Phase 2 TVB-3567 acne trial in 2026, pending Phase 1 completion</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D SPENDING - Q4 research and development expense declined by 52.6% yr/yr to $6.7 mln, contributing to a narrower net loss</p></li></ul><p>Company press release: <span>ID:nGNX7NkT6k</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.29</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$9.57 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 11 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Sagimet Biosciences Inc is $27.00, about 388.2% above its March 10 closing price of $5.53</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sagimet Biosciences Q4 net loss narrows as R&D expenses fall</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSagimet Biosciences Q4 net loss narrows as R&D expenses fall\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-11 19:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/SGMT\">Sagimet Biosciences</a> Q4 net loss narrows as R&amp;D expenses fall</title></head><body><p><span>Overview</span></p><ul><li><p>U.S. biopharma firm's Q4 net loss narrowed yr/yr</p></li><li><p>Q4 research and development expense declined from prior year</p></li><li><p>Company completed Phase 1 trial for denifanstat/resmetirom combo and saw positive Phase 3 acne data from partner</p></li></ul><p><span>Outlook</span></p><ul><li><p>Sagimet plans Phase 2 denifanstat/resmetirom trial in F4 MASH patients in 2H 2026</p></li><li><p>Company expects to start Phase 2 TVB-3567 acne trial in 2026, pending Phase 1 completion</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D SPENDING - Q4 research and development expense declined by 52.6% yr/yr to $6.7 mln, contributing to a narrower net loss</p></li></ul><p>Company press release: <span>ID:nGNX7NkT6k</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.29</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$9.57 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 11 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Sagimet Biosciences Inc is $27.00, about 388.2% above its March 10 closing price of $5.53</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL1N3ZZ0JR:1","article_id":"2618941265","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618941265","pubTimestamp":1773229167,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sagimet Biosciences Q4 net loss narrows as R&D expenses fallOverviewU.S. biopharma firm's Q4 net loss narrowed yr/yrQ4 research and development expense declined from prior yearCompany completed Phase ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SGMT":"Sagimet Biosciences Inc."},"translate_title":"随着研发费用下降，Sagimet Biosciences第四季度净亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SGMT":0.9},"content_text":"Sagimet Biosciences Q4 net loss narrows as R&D expenses fallOverviewU.S. biopharma firm's Q4 net loss narrowed yr/yrQ4 research and development expense declined from prior yearCompany completed Phase 1 trial for denifanstat/resmetirom combo and saw positive Phase 3 acne data from partnerOutlookSagimet plans Phase 2 denifanstat/resmetirom trial in F4 MASH patients in 2H 2026Company expects to start Phase 2 TVB-3567 acne trial in 2026, pending Phase 1 completionResult DriversR&D SPENDING - Q4 research and development expense declined by 52.6% yr/yr to $6.7 mln, contributing to a narrower net lossCompany press release: ID:nGNX7NkT6kKey DetailsMetricBeat/MissActualConsensus EstimateQ4 EPS-$0.29Q4 Net Income-$9.57 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 11 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Sagimet Biosciences Inc is $27.00, about 388.2% above its March 10 closing price of $5.53For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618941265","isCrawlerRequest":true}